Possible quality and outcomes framework role to increase aspirin prophylaxis in Wales

Quality in Primary Care

Volumn 14, Issue 4, 2006, Pages 239-242

  Morgan, Gareth ^a  

^a Welsh Aspirin Group   (United Kingdom)

Author keywords

Aspirin; Cost saving; Policy QOF; Vascular events

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COST CONTROL; DRUG CONTRAINDICATION; FUNDING; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH PROMOTION; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL COST; LOW DRUG DOSE; NATIONAL HEALTH SERVICE; PRIMARY HEALTH CARE; PUBLIC HEALTH; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

EID: 33846280063     PISSN: 14791072     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Morgan G. The existing and emerging uses of aspirin. Basic and Clinical Pharmacology and Toxicology (in press).
2. Lamotte M, Annemans L, Evers T and Kubin M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics 2006;24:155-69.
3. Pignone M, Earnshaw S, Tice JA and Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease in men: a cost-utility analysis. Annals of Internal Medicine 2006;144:326-36.
4. Elwood P, Hughes J, Morgan G, Brown G and Longley M. A survey of aspirin use for vascular prophylaxis in Wales. Quality in Primary Care 2005;13:201-4.
5. Morgan G. Quality and outcome framework in Carmarthenshire, south-west Wales. Quality in Primary Care 2005;4:97-100.
6. Fleetcroft R and Cookson R. Do the incentive payments in the new NHS contract for primary care reflect likely populations health gains? Journal of Health Services Research and Policy 2006; 11:27-31.
7. Morgan G. A health impact assessment of increased aspirin use in Wales. Public Health 2005;119:734-7.
8. Heart Protection Study Collaborative Group (writing committee: Mihaylova B, Briggs A, Armitage J, Parish S, Gray A and Collins R). Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals. The Lancet 2005;365:1779-85.
9. Patrono C, Garcia Rodriguez G, Landolfi R and Baigent C. Low-dose aspirin for the prevention of atherothrombosis. New England Journal of Medicine 2005; 353:2373-83.
10. Morgan G. What next for low-dose aspirin? Journal of Epidemiology and Community Health 2005;59(1):3-4.